Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasm Metastasis × ALX148 × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 HER2-expressing Cancers 1 Composite Lymphoma 1 Breast Neoplasms 1

Interventions

pembrolizumab 40 Nivolumab 21 Gemcitabine 20 Paclitaxel 17 Cyclophosphamide 17 Capecitabine 16 fludarabine 11 aldesleukin 11 Ipilimumab 11 Trastuzumab 10 Docetaxel 10 130-nm albumin-bound paclitaxel 10 Interleukin-2 8 Bevacizumab 8 Albumin-Bound Paclitaxel 8 Radiosurgery 7 Cisplatin 7 Biopsy 7 fludarabine phosphate 6 Temozolomide 6 Specimen Handling 6 Irinotecan 6 Fluorouracil 6 Cetuximab 6 Carboplatin 6 avelumab 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Magnetic Resonance Spectroscopy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07007559 2026-02-03

ASPEN-09

ALX Oncology Inc.

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡